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Abstract 
Objectives: Variants appearing de novo in genes regulating key neurodevelopmental processes and/or in 
non-coding cis-regulatory elements (CREs), as enhancers, may increase the risk for schizophrenia. However, 
CREs involvement in schizophrenia needs to be explored more deeply. 
Methods: We investigated de novo copy-number variations (CNVs) in the whole-genomic DNA obtained from 
46 family trios of schizophrenia probands by using the Enhancer Chip, a customised array CGH able to 
investigate the whole genome with a 300-kb resolution, specific disease loci at a ten-fold higher resolution, 
and which was highly enriched in probes in more than 1,250 enhancer elements selected from Vista Enhancer 
Browser. 
Results: In seven patients, we found de novo CNVs, two of which overlapped VISTA enhancer elements. De 
novo CNVs encompass genes (CNTNAP2, MAGI1, TSPAN7 and MET) involved in brain development, while 
that involving the enhancer element hs1043, also includes ZIC1, which plays a role in neural development 
and is responsible of behavioural abnormalities in Zic mutant mice. 
Conclusions: These findings provide further evidence for the involvement of de novo CNVs in the 
pathogenesis of schizophrenia and suggest that CNVs affecting regulatory enhancer elements could 
contribute to the genetic vulnerability to the disorder. 
 
In the last few years, different strategies have been combined to investigate the genetic contribution to the 
pathogenesis of schizophrenia. Large genome-wide association studies (GWASs) and high-throughput DNA 
sequencing technologies have identified common and rare single-nucleotide variants as well as rare copy-
number variations (CNVs) as potential risk factors (for review see Chen et al. 2015). everal case-control 
studies have also reported an increased genomic burden in the case population for duplications and deletions 
sized 100 kb and larger at recurrent loci (International Schizophrenia Consortium 2008; Walsh et al. 2008). 
To date, at least 15 distinct genomic regions with changes in their copies have been associated with an 
increased risk for schizophrenia (Rees et al.2014). 
In this scenario, it has been postulated that genetic variants may appear de novo to increase the population 
risk for the disorder (Xu et al. 2011, 2012; Fromer et al. 2014). The analysis of de novo variants in 
schizophrenia has included not only CNVs but also single-nucleotide and small InsDel variants (Girard et al.; 
Xu et al. 2011, 2012; Mulle et al. 2010). Specifically, rare de novo CNVs that disrupt genes involved in 
signalling and neurodevelopmental pathways as well as in synaptic plasticity have been associated to 
schizophrenia (Walsh et al. 2008; Kirov et al. 2012). Moreover, some lines of evidence have suggested that 
sequence variants or CNVs in non-coding regions of the human genome, as those occurring in cis-regulatory 
elements (CREs) such as promoters or enhancers, could contribute to a wide spectrum of psychiatric 
conditions, including schizophrenia (Visel et al. 2004; Walsh et al. 2008; International Schizophrenia 
Consortium 2008; Cooper et al. 2011; Malhotra et al. 2011; Xiao et al. 2017; Li and Weiberger 2017), very 
probably by altering transcriptional regulation in the brain (Roussos et al. 2014). A CRE is a non-coding DNA 
sequence regulating the spatiotemporal expression of target genes localised near or distant to the CRE itself. 
GWASs have identified many disease- and trait-associated non-coding genetic variants enriched in regulatory 
DNA marked by deoxyribonuclease I (DNase I) hypersensitive sites (DHSs), which lie within non-coding CREs 
(Maurano et al. 2012). These disease- and trait- associated variants can perturb transcription factor 
recognition sequences, the allelic chromatin state and regulatory networks (Won et al.). Furthermore, 
Roussos et al. (2014 ) recently demonstrated that, in post-mortem human brain tissue, the risk variant of the 
L-type calcium channel (CACNA1C) gene, a well-established schizophrenia risk locus (Ripke et al. 2013), 
interacts physically with a distal enhancer and this is responsible for a reduced gene expression and 
transcriptional activity. Thus, it seems plausible that CRE mutations may contribute to the genetic risk for 
schizophrenia. 
CREs elements have been conserved across species, and range from some hundred to few thousand base 
pairs (Bejerano et al. 2004). The detection of CNVs affecting these sequence motifs could be hampered by a 
size-dependent reduction in sensitivity and specificity of GWAS or whole-genome SNP-CGH array approaches 
(Zhang et al. 2011). We recently developed the Enhancer Chip (Savarese et al. 2012), a customised array CGH 
design that is specifically oriented to investigate CNVs in evolutionarily conserved genomic regions 
corresponding to putative enhancer sequence motifs. The Enhancer Chip not only allows the analysis of all 
the human genome with a 300-kb resolution, but also permits to investigate specific disease loci, including 
those related to psychiatric conditions, at a ten-fold higher resolution. In addition, it is also able to test, at 
high resolution, over 1,250 enhancer elements selected from the Vista Enhancer Browser (Visel et al. 2007). 
These evolutionarily conserved sequence motifs were experimentally validated for their capacity to drive, in 
vivo, the expression of a reporter gene in transgenic mouse embryos at day 11.5 (E11.5) in a well-established 
enhancer assay that links the human conserved fragment to a minimal mouse heat shock promoter fused to 
a lacZ reporter gene (Kothary et al. 1989; Nobrega et al. 2003; Pennacchio et al. 2006). 
In the present study, we used this tool to analyse the whole-genomic DNA of an Italian cohort of 
schizophrenia patients and their parents. The analysis of these family trios provides further evidence for the 
involvement of de novo CNVs in the pathogenesis of schizophrenia, and suggests that copy-number changes 
affecting regulatory enhancer elements of the human genome should be considered as potential contributors 
to the genetic vulnerability to schizophrenia. 
Materials and methods 
Subjects 
Study participants were part of a wider multicenter study, involving an Italian cohort of schizophrenia 
patients living in the community and consecutively seen at the outpatient units of 26 Italian university 
psychiatric clinics and/or mental health departments (Galderisi et al. 2014). According to that study, patients 
were enrolled on the basis of the following inclusion and exclusion criteria. Inclusion criteria were: (a) a 
diagnosis of schizophrenia according to DSM-IV, confirmed with the Structured Clinical Interview for DSM-IV 
– Patient version (SCID-I-P); (b) age range between 18 and 66 years; (c) no family history of schizophrenia; 
(d) living and available parents. Exclusion criteria were: (a) history of head trauma with loss of consciousness; 
(b) history of moderate to severe mental retardation or of neurological diseases; (c) history of alcohol and/or 
substance abuse in the last 6 months; (d) current pregnancy or lactation; (e) inability to provide an informed 
consent. 
Fifty-seven patients, 42 males and 15 females, aged 19–50 years (mean ± SD 31.2 ± 7.0 years), with their 
parents were included in the study. Patients were on stable antipsychotic treatment for at least 3 months: 
nine of them were treated with haloperidol (1–6 mg/day), ten with aripiprazole (15–30 mg/day), eight with 
clozapine (100–300 mg/day), twelve with olanzapine (5–25 mg/day), seven with paliperidone (6–12 mg/day), 
ten with risperidone (2–6 mg/day) and one with ziprasidone (160 mg/day). Patients underwent a 
comprehensive clinical assessment (Galderisi et al. 2014) that included: (a) the Positive and Negative 
Syndrome Scale (PANSS, Kay et al. 1987  that rates symptom severity; (b) the Brief Negative Symptom Scale 
(BNSS), which explores five negative symptoms domains (anhedonia, asociality, avolition, blunted affect and 
alogia) (Mucci et al. 2015); (c) the MATRICS (Measurement and Treatment Research to Improve Cognition in 
Schizophrenia) Consensus Cognitive Battery (MCCB), which assesses seven distinct cognitive domains 
(processing speed, attention/vigilance, working memory, verbal learning, visual learning, social cognition, 
and reasoning and problem solving) (Kern et al. 2008; Nuechterlein et al. 2008). 
 
The study was approved by the Ethics Committee of the University of Campania ‘Luigi Vanvitelli’ and was 
carried out in accordance with the Declaration of Helsinki for experiments involving humans. All the 
participants signed a written informed consent to participate after receiving a comprehensive explanation of 
the study procedures and goals. 
All the participants provided blood samples for genomic DNA extraction according to standard procedures. 
Concentration and purity of all DNA samples were assessed using spectrophotometer (Nanodrop ND 1000, 
Thermo Scientific Inc., Rockford, IL, USA) and the Amelogenin PCR test was carried out to exclude any 
erroneous sex assignation during data/sample collection. In addition, DNA samples were also genotyped with 
a panel of six autosomal highly heterozygous STR markers to validate kinship relationships in family trios. 
According to the above criteria, whole-genomic DNA was obtained from 57 family trios, but only 46 of them 
passed quality control and were further investigated in this study. 
 
Array CGH analysis 
Genomic DNA was analysed using the Enhancer Chip, a customised array CGH developed using the Agilent 
SurePrint G3 8X60K format (Savarese et al. 2012), and able to investigate the whole genome with a 300-kb 
resolution, specific disease loci at a ten-fold higher resolution (for more details see Supplemental Table S2 in 
Savarese et al. 2012), and more than 1,250 highly enriched in probes in VISTA enhancer motifs for their 
potential pathogenic role. 
Ten sex-matched anonymous DNA samples from healthy individuals were pooled at equimolar concentration 
and used as male or female reference DNA samples in all the array CGH experiments. Labelling and 
hybridisation were performed according to the manufacturer’s specifications (Agilent Oligonucleotide Array-
Based CGH for Genomic DNA Analysis protocol, version 6.1; Agilent Technologies, USA) and as previously 
reported (Piluso et al. 2011; Savarese et al. 2012). Scanned array images were analysed using Feature 
Extraction software (version 10.5.1.1; Agilent Technologies). Graphical overview and analysis of data were 
obtained using DNA Analytics as part of Agilent Genomic Workbench software (version 7.0.4.0; Agilent 
Technologies). 
To identify copy-number changes we used the Aberration Detection Method 2 (ADM-2) algorithm (Agilent 
Technologies) for data that passed QC metrics testing. The ADM-2 algorithm identifies all aberrant intervals 
in a given sample with consistently high or low log ratios based on the statistical score. The statistical score 
represents the deviation of the average of the log ratios from the expected value of zero, in units of standard 
deviation. The algorithm searches for intervals in which a statistical score based on the average quality 
weighted log ratio of the sample and reference channels exceeds a user specified threshold. The threshold is 
normally set to 6. In our experiments, the threshold was set between 5 and 7 and it was empirically chosen 
for each test, considering the noise reduction in control hybridisations (reference vs reference). The 
aberration filter was set to select aberrant regions with at least three targets showing the same direction in 
copy-number change, and to exclude aberrant regions if the average log2 ratio within the region was less 
than the value of Derivative Log Ratio Spread. 
Identified CNVs were compared with the Database of Genomic Variants (http://dgv.tcag.ca/) and with the 
Decipher database (https://decipher.sanger.ac.uk/) to facilitate interpretation. 
 
Validation experiments 
Potentially pathogenic CNVs were further validated by reanalysing DNA samples on Enhancer Chip after dye-
swapped labelling or alternatively using Agilent SurePrint G3 CGH ISCA v2 8x60K platform, when regions of 
interest were adequately covered by probes. In addition, CNV validation was also performed by quantitative 
amplification of specific genomic regions (primer pairs available in Supplementary Table S1 available online) 
on CFX96 Real-Time PCR Detection System (Bio-Rad Laboratories, USA) using iQ SYBR Green Supermix (Bio-
Rad Laboratories), according to the manufacturer's instructions. Each assay was performed in triplicate and 
results were normalised and analysed using CFX Manager Software Version 1.5 (Bio-Rad Laboratories). For 
some of the identified CNVs, 5′ and 3′ breakpoint boundaries were further refined by Real-Time PCR 
(Supplementary Table S1). 
 
Bioinformatic analysis 
For genes in CNVs never described previously as potentially associated to psychiatric conditions, GeneMANIA 
(www.genemania.org) was used to generate protein-protein interaction (PPI) and co-expression networks 
(Mostafavi et al. 2008; Warde-Farley et al. 2010). This interface is able to create interaction networks, 
highlighting the most representative pathways, on the basis of data obtained from currently available 
genomics and proteomics databases. The algorithm contains two import components: a linear regression-
based algorithm that is used to calculate a single, composite functional association network from multiple 
networks that were derived from different proteomic or genomic data sources and a component that 
predicts gene functions (Warde-Farley et al. 2010). Network nodes scores and gene list-specific weights are 
reported in Supplementary Tables S2 and S3. 
 
Results 
Evaluating array CGH results, all mechanisms of inheritance were considered. No rearrangements were found 
in accordance with an autosomal recessive or X-linked model of inheritance. We then considered de novo 
CNVs spanning more than 20 kb, in which no copy-number polymorphisms were present. To our knowledge, 
de novo CNVs here described were not previously reported. 
We found two deletions and five duplications in seven unrelated schizophrenia patients (Table 1). In 
particular, a de novo heterozygous deletion of about 50 kb in size was found at 7q35 in the patient S-23 
(Supplementary Figure S1). This deletion encompassed the intron 12 of CNTNAP2, for which 
haploinsufficiency was previously associated to epilepsy and schizophrenia (Friedman et al. 2008). The closer 
CNTNAP2 exon fell in the 3′ breakpoint boundary, but it did not show to be deleted by using qPCR 
(Supplementary Figure S1). Patient S-36 showed a de novo duplication about 350 kb long at 3p14.1, involving 
MAGI1 (Supplementary Figure S1). This gene and the closely related MAGI2 have already been associated to 
schizophrenia (Karlsson et al. 2012; Koide et al. 2012). Male patient S-60 had a de novo duplication of about 
50 kb in size at Xp11.4, involving the last six exons of TSPAN7, a gene recently associated to X-linked 
intellectual disability, as well as autism and schizophrenia (Noor et al. 2009; Piton et al. 2011; Utine et al. 
2012) (Supplementary Figure S1). 
Table 1. CNVs in schizophrenia family trios. 
 
 
For CNVs identified in patients S-40 and S-75, 5′ and 3′ breakpoint boundaries were further defined by qPCR 
(Table 1 and Supplementary Figure S2). We therefore investigated whether genes included in these de novo 
putatively damaging copy-number changes were clustered in functional or PPI networks, in some way related 
to schizophrenia. By performing GeneMANIA in silico analysis (Koide et al. 2012; Utine et al. 2012), we 
observed that, among 31 genes located in these CNVs, only eight appeared to be interconnected, defining 
two distinct functional and PPI networks (Figure 1). Interestingly, the heterozygous 700-kb long deletion at 
7q31.2 (patient S-75), encompassed three genes (CAV1, CAV2 and MET), which are implicated in neuronal 
migration and development and whose variants have been associated with schizophrenia (Burdick et al. 
2010; Allen et al. 2011). The other genes investigated seem to be in part co-expressed and integrated in 
interesting functions, such as Wnt signalling pathway, glycosylation, endocytosis and cell migration (Wurst 
and Prakash, 2014) (Figure 1). 
 Enhancer Chip also permitted to identify two de novo CNVs overlapping VISTA enhancer elements. Patient S-
45 showed a heterozygous 234-kb long duplication at 3q24, which includes ZIC1 and the regulatory element 
hs1043, while patient S-131 presented a heterozygous duplication of about 55 kb at Xq21.1, which involves 
the regulatory element hs582 (Table 1 and Supplementary Figure S3). 
 
When patients carrying de novo CNVs were compared to those not carrying de novo CNVs, no significant 
differences emerged in PANSS, BNSS and MCBB scores. 
 
Discussion 
To our knowledge, this is the first genetic study of schizophrenia that includes an analysis of copy-number 
changes in CRE of the human genome. Our cohort of family trios from schizophrenia patients was 
investigated using the Enhancer Chip (Savarese et al.), a customised array CGH designed not only to analyse, 
at high resolution, the whole human genome, but also the potential pathogenic role of over 1,250 VISTA 
enhancer sequence motifs (Pennacchio et al. 2006). Array CGH analysis identified a total of seven de novo 
rearrangements in unrelated patients with schizophrenia. In two cases, a VISTA enhancer element was 
involved. 
 
One patient (S-23) showed a de novo heterozygous deletion affecting only part of the intron 12 of CNTNAP2. 
This gene is highly conserved and expressed in different areas of the brain, where it encodes for Caspr2 
protein, which has been implicated in neuronal migration (Allen et al. 2011). Mutations in CNTNAP2 have 
already been described in members of Old Order Amish families presenting a neuropathological phenotype 
with cortical dysplasia and focal epilepsy, as well as in two other unrelated families with Pitt-Hopkins-like 
syndrome (Strauss et al. 2006; Wurst and Prakash, 2014). In addition, several studies indicate that CNTNAP2 
is an autism susceptibility gene (Alarcón et al. 2008; Zweier et al. 2009). Recently, Friedman et al. (2008) first 
demonstrated an association between CNTNAP2 and schizophrenia, describing different gene deletions in 
three unrelated patients with schizophrenia and autism. Like our patient who showed a deletion involving 
only the intron 12 of CNTNAP2, one of Friedman’s patients had a small deletion of the CNTNAP2 intron 3. 
The pathogenic significance of these intronic rearrangements remains to be clarified. For patient S-23, the 
deleted region of intron 12 seems to be enriched in putative transcription factor binding sites conserved in 
the human/mouse/rat alignment, as well as DNaseI hypersensitivity clusters that could perturb CNTNAP2 
expression or act at distance, affecting other genes (http://genome.ucsc.edu). 
 
However, functional analysis of this intronic CNTNAP2 deletion has been hampered by the CNTNAP2 
expression pattern restricted to the nervous system (Poliak et al. 1999). At present, this rearrangement 
should only be considered as a variant of uncertain significance. 
 
The de novo microduplication at 3p14.1, identified in patient S-36, encompasses MAGI1. MAGI1 encodes a 
postsynaptic scaffolding protein interacting with a multitude of molecules that have been implicated in the 
pathogenesis of bipolar disorders or schizophrenia, such as neuroligins, β-catenin, neuregulin receptor ErbB4 
and glutamate receptors (Nishimura et al. 2002; Iida et al. 2004; Buxbaum et al. 2008; Emtage et al. 2009). 
Deletions and duplications of MAGI1 have recently been described in a study of 277 DNA samples from 48 
families with a clinical diagnosis of bipolar disorder or schizophrenia (Karlsson et al. 2012). In this study, the 
authors followed up an apparently highly penetrant CNV from a family-based analysis, investigating 4,084 
unrelated cases and carrying out a pooled analysis on a total of 10,925 patients and 16,747 controls. 
Statistical data analysis supported the hypothesis that 3p14 could be a region of interest for schizophrenia 
(Karlsson et al. 2012). 
 
For the de novo duplication at Xp11.4, which involves TSPAN7 and was observed in patient S-60, it is worth 
noting that this gene is related to synaptic functions and encodes a cell-surface protein of the tetraspanin 
family, involved in cell growth and motility (Bassani et al. 2012). Rare variants of TSPAN7 have been found to 
be associated with X-linked intellectual disability in patients with autism spectrum disorders, and have been 
suggested to have a role also in schizophrenia (Noor et al. 2009; Piton et al. 2011; Utine et al.). 
 
In patient S-75, the de novo heterozygous deletion at 7q31.2 included CAV1, CAV2 and MET, whose variants 
have been already associated to schizophrenia in different ways. In particular, the CAV1 and CAV2 genes 
encode caveolins, which are multi-functional scaffolding proteins of the inner surface of caveolae, small 
invaginations of the plasma membrane, and are involved in essential cellular functions including vesicular 
trafficking, lipid homeostasis and signal transduction (Ostrom 2002; Cohen et al. 2004). Recently, an 
insertional mutation disrupting CAV1 has been identified as a rare structural variant associated with 
schizophrenia (Allen et al. 2011). Moreover, it has been observed that CAV1 knockout mice exhibited 
increased sensitivity to the psychotomimetic effects of phencyclidine (Allen et al.), a phenomenon also 
observed in patients with schizophrenia (Lahti et al. 1995), and that they were unresponsive to the 
normalising effects of the atypical antipsychotics clozapine and olanzapine on phencyclidine-induced 
disruption of pre-pulse inhibition, a deficit that has been linked to abnormalities of sensorimotor gating 
observed in patients with schizophrenia (Javitt and Freedman 2015). These findings support a role for this 
gene in the pathophysiology of schizophrenia. The MET proto-oncogene, instead, is a cancer-related gene 
involved in the metastasis of several forms of cancer, the repair and development of peripheral organs 
(Birchmeier et al. 2003; Tahara et al. 2003), as well as in the cortical and cerebellar development (Ieraci et al. 
2002). Interestingly, MET seems to be sensitive to the haploinsufficiency, with a loss-of-function index (pLI) 
equal to 1 in the ExAC Browser (exac.broadinstitute.org). Recently, Burdick et al. (2010) examined 21 SNPs 
of this gene in a cohort of schizophrenic patients and found that individuals carrying at least one copy of the 
most common haplotype were significantly less likely to develop schizophrenia as compared with those 
carrying no copies. Furthermore, MET haplotype carriers had significantly better cognitive performance than 
non-carriers, although the results did not reach statistical significance. 
 
For patient S-40, the de novo heterozygous duplication at 19p13.13 encompassed 22 genes (Table 1), some 
of which clustered in glycobiology pathway, including sphingolipid metabolism and glycosyltransferases 
(Figure 1(B)). Disruption of sphingolipid metabolism could result in widespread effects, related to diverse 
pathological deficits already described in schizophrenia, including myelination and oligodendrocyte function 
(Narayan et al. 2009). Three fucosyltransferase genes (FUT3, FUT5 and FUT6) map in the duplicated region 
(Costache et al. 1997), and plasma α1,3-fucosyltransferase deficiency was detected in Japanese patients with 
schizophrenia (Yazawa et al. 1999; Tanaka et al. 2001). Post-translational protein modifications can have a 
role in the pathophysiology of schizophrenia. α1,6-fucosyltransferase (Fut8–/–)-deficient mice exhibited 
multiple behavioural abnormalities consistent with a schizophrenia-like phenotype (Fukuda et al. 2011), 
while dysregulated fucosyltransferase expression was observed in the superior temporal gyrus of elderly 
patients with schizophrenia compared with healthy controls (Mueller et al. 2017). 
 
In schizophrenia, most of the reported rare de novo mutations seem to be enriched in genes related to 
chromatin remodelling, synaptic organisation and plasticity, as well as to be associated to autism or 
intellectual disability (Fromer et al. 2014; McCarthy et al. 2014). Some of genes encompassed in de novo 
CNVs reported here (CNTNAP2, MAGI1, TSPAN7, CAV1 and CAV2) seem to have similar characteristics 
(Horresh et al. 2008; Head et al. 2010; Zheng et al. 2011; Bassani and Passafaro 2012). 
 
The most innovative finding of our study is that the Enhancer Chip allowed us to detect rearrangements 
covering enhancer elements. The 234-kb long duplication at 3q24, which we detected in patient S-45, 
includes the enhancer element hs1043 and its flanking gene ZIC1. Interestingly, ZIC1 is a member of a zinc-
finger protein family that plays a crucial role in neural development (Aruga 2004). In addition, behavioural 
abnormalities have been observed in Zic mutant mice, resembling human neurological and psychiatric 
conditions (Ogura et al. 2001). In addition, ZIC1 and other 11 genes were found differentially expressed in 
the mouse brain after treatment with valproate at human therapeutic concentrations (Chetcuti et al. 2006). 
Therefore, ZIC1 dysregulation could be involved in the therapeutic action of this drug, which acts as mood 
stabiliser in people with bipolar or schizoaffective disorder. Interestingly, the regulatory enhancer element 
hs1043 was able to drive reporter gene expression in hindbrain (rhombencephalon) and neural tube of 
transgenic mouse embryos at stage E11.5 (experimental data for hs1043 are freely available at 
https://enhancer.lbl.gov/). 
 
The 55-kb long duplication found at Xq21.1 (patient S-131) seems deserted of genes, only including the 
regulatory element hs582, representing the unique evolutionarily conserved sequence motif in this interval. 
To the present, we can only speculate on pathogenic significance of this arrangement. Nevertheless, hs582 
was able to drive reporter gene expression in forebrain of transgenic mouse embryos at stage E11.5 
(experimental data for hs582 are freely available at https://enhancer.lbl.gov/). 
 
Interestingly, the increased density of probes in enhancer elements also permitted to better characterise the 
5′ breakpoint boundary that, for both rearrangements, falls into the enhancer element, possibly perturbing 
its function (Supplementary Figure S3). 
 
At present, it is not simple to explain the possible role of enhancer elements in the pathophysiology of human 
brain disorders, because little is known about their gene targets. However, previous studies have established 
the important regulatory role of the enhancers on transcriptome organisation during neurodevelopment and 
adulthood (Wenger et al. 2013; Andersson et al. 2014). Moreover, Roussos et al. (2014) suggested that risk-
allele-specific changes in enhancer elements could affect the spatiotemporal organisation of the 
transcriptome that, when combined with other derangements, could lead to schizophrenia. 
 
Very recently, a high-resolution three-dimensional analysis of chromatin contacts during human 
corticogenesis permitted large-scale annotation of previously uncharacterised regulatory elements, 
identifying hundreds of genes that physically interact with enhancers and that are associated with human 
cognitive function (Won et al. 2016). Some non-coding variants identified in GWAS schizophrenia studies 
(Schizophrenia Working Group of the Psychiatric Genomics Consortium 2014) were enriched in some of these 
selected chromatin regions, supporting their role in the dysregulation of specific genes related to human 
brain development and cognition. Enhancer elements that we found in CNVs, seem to be not enriched in the 
above reported experimental model. 
 
The lack of precise data on copy-number changes affecting enhancer elements is due to the absence of 
appropriate methods for their identification. Our study represents a first attempt in using a dedicated tool, 
the Enhancer Chip, to investigate the role of regulatory elements in the pathogenesis of schizophrenia. 
However, the relevance of mutations in enhancer elements for the pathophysiology of schizophrenia needs 
to be established in larger studies including also control groups. 
 
As for data presented here, rare CNVs can only explain a very limited number of schizophrenia cases and do 
not seem to confer peculiar phenotypic aspects, since patients carrying these de novo CNVs did not differ 
from those not carrying them on symptom severity, psychopathological negative dimensions and cognitive 
functions. Whole-exome sequencing (WES) studies are now providing the most extensive datasets of de novo 
mutations in schizophrenia (Xu et al. 2011; Fromer et al. 2014; Iossifov et al. 2014; McCarthy et al. 2014; 
Kranz et al. 2015; Rees et al. 2015), extending the number of genes and biological pathways likely involved 
in this and related disorders. WES is the future perspective to complete the genetic investigation of this 
cohort of schizophrenia patients. 
 
GWA, CNVs and NGS studies have permitted to identify recurrent and rare genetic variants that contribute 
to schizophrenia and, in some cases, overlap other psychiatric disorders and neurodevelopmental syndromes 
(Modai and Shomron, 2016). Genetic analysis strongly suggests that schizophrenia is biologically 
heterogeneous, but it also provides the way to better classify patients in unique subgroups, useful to test 
new drugs or the efficacy of those now in use (Giegling et al. 2017; Matsumoto et al. 2017). Relatively 
homogeneous groups, defined using WES and array CGH, could constitute an initial step for building more 
accurate risk-prediction models in the attempt to develop personalised medicine approaches (Fraguas et al. 
2017). 
 
In conclusion, in a cohort of Italian schizophrenia patients, we found a total of seven de novo CNVs consisting 
of two deletions and five duplications. Two of these rearrangements that involved MAGI1 and TSPAN7 genes 
have been already described in association to schizophrenia and/or bipolar disorder as well as to X-linked 
intellectual disability with autistic spectrum. For the others, some of the involved genes are known to play 
critical roles in brain development, neuronal migration and synaptogenesis, which are processes supposed 
to be involved in the risk of schizophrenia. Only in two cases did we observe rearrangements of enhancer 
modulatory elements whose function in the human brain still await to be identified. These findings provide 
a significant contribution to the identification of rare CNVs associated to schizophrenia and pave the way to 
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